Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21454476 | 1.00 | HSD17B10 (0.42) | HSD17B10SIGMAR1SLC6A9NPC1CHRM5 | |
| SCHEMBL21454477 | 0.98 | HSD17B10 (0.44) | HSD17B10SIGMAR1SLC6A9NPC1CHRM5 | |
| SCHEMBL10284339 | 0.94 | HSD17B10 (0.47) | HSD17B10SIGMAR1SLC6A9NPC1CHRM5 | |
| SCHEMBL21764427 | 0.94 | HSD17B10 (0.47) | HSD17B10SIGMAR1SLC6A9NPC1CHRM5 | |
| SCHEMBL20202265 | 0.94 | HSD17B10 (0.47) | HSD17B10SIGMAR1SLC6A9NPC1CHRM5 | |
| SCHEMBL24220956 | 0.94 | HSD17B10 (0.47) | HSD17B10SIGMAR1SLC6A9NPC1CHRM5 | |
| SCHEMBL21764630 | 0.93 | SIGMAR1 (0.38) | HSD17B10SIGMAR1SLC6A9NPC1CHRM5 | |
| SCHEMBL29299636 | 0.93 | SIGMAR1 (0.38) | HSD17B10SIGMAR1SLC6A9NPC1CHRM5 | |
| SCHEMBL15982293 | 0.92 | SIGMAR1 (0.38) | HSD17B10SIGMAR1SLC6A9NPC1CHRM5 | |
| SCHEMBL14487492 | 0.90 | SIGMAR1 (0.44) | SIGMAR1NPC1CHRM5CHRM3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2023-10-19 | — | — | US | disclosed |
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2023-10-19 | — | — | US | disclosed |
| US-11746126-B2 | Bicyclic peptide ligands with detectable moieties and uses thereof | Bicyclerd Limited (GB) | 2023-09-05 | — | — | US | disclosed |
| US-11746126-B2 | Bicyclic peptide ligands with detectable moieties and uses thereof | Bicyclerd Limited (GB) | 2023-09-05 | — | — | US | disclosed |
| US-11707539-B2 | FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707539-B2 | FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-07-25 | — | — | US | disclosed |
| US-20220162241-A1 | Chelated PSMA Inhibitors | CANCER TARGETED TECH LLC (US) | 2022-05-26 | — | — | US | disclosed |
| US-11225496-B2 | Chelated PSMA inhibitors | CANCER TARGETED TECHNOLOGY LLC (US) | 2022-01-18 | — | — | US | disclosed |
| US-11147889-B2 | Albumin-binding PSMA inhibitors | CANCER TARGETED TECHNOLOGY LLC (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210079045-A1 | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE MOIETIES AND USES THEREOF | Bicyclerd Limited (GB) | 2021-03-18 | — | — | US | disclosed |
| US-10919937-B2 | Bicyclic peptide ligands and uses thereof | BICYCLETX LIMITED (GB) | 2021-02-16 | — | — | US | disclosed |
| US-20200131228-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | BICYCLETX LIMITED (GB) | 2020-04-30 | — | — | US | disclosed |
| US-20200061218-A1 | Albumin-Binding PSMA Inhibitors | CANCER TARGETED TECHNOLOGY LLC | 2020-02-27 | — | — | US | disclosed |
| US-20190309000-A1 | Chelated PSMA Inhibitors | CANCER TARGETED TECHNOLOGY LLC | 2019-10-10 | — | — | US | disclosed |
| US-10166301-B2 | Chelated PSMA inhibitors | CANCER TARGETED TECHNOLOGY LLC (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180207298-A1 | Chelated PSMA Inhibitors | CANCER TARGETED TECHNOLOGY LLC | 2018-07-26 | — | — | US | disclosed |
| US-9974869-B2 | Chelated PSMA inhibitors | CANCER TARGETED TECHNOLOGY LLC (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170072075-A1 | Chelated PSMA Inhibitors | CANCER TARGETED TECHNOLOGY LLC | 2017-03-16 | — | — | US | disclosed |
| US-20170072075-A1 | Chelated PSMA Inhibitors | CANCER TARGETED TECHNOLOGY LLC | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207298-A1 | Chelated PSMA Inhibitors | FOLH1, KLK3, PSMA1 | HSD17B10 3737/4885SIGMAR1 3316/4885SLC6A9 2709/4885 |
| US-20220162241-A1 | Chelated PSMA Inhibitors | FOLH1, PSMA1, PSMA2 | HSD17B10 2817/4885SIGMAR1 3119/4885SLC6A9 256/4885 |
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | FAP, APC, FIBP | HSD17B10 3607/4885SIGMAR1 4436/4885SLC6A9 4564/4885 |
| US-11225496-B2 | Chelated PSMA inhibitors | FOLH1, PSMA1, PSMA2 | HSD17B10 2817/4885SIGMAR1 3119/4885SLC6A9 256/4885 |
| US-10166301-B2 | Chelated PSMA inhibitors | FOLH1, KLK3, PSMA1 | HSD17B10 3737/4885SIGMAR1 3316/4885SLC6A9 2709/4885 |
| US-11147889-B2 | Albumin-binding PSMA inhibitors | PSMA1, ALB, PSMA2 | HSD17B10 3053/4885SIGMAR1 3315/4885SLC6A9 562/4885 |
| US-20200131228-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | VIP, NGLY1, BID | HSD17B10 4052/4885SIGMAR1 1240/4885SLC6A9 4691/4885 |
| US-11707539-B2 | FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto | FAP, APC, FIBP | HSD17B10 3607/4885SIGMAR1 4436/4885SLC6A9 4564/4885 |
| US-11746126-B2 | Bicyclic peptide ligands with detectable moieties and uses thereof | VIP, NGLY1, GRPR | HSD17B10 4114/4885SIGMAR1 1983/4885SLC6A9 4781/4885 |
| US-20190309000-A1 | Chelated PSMA Inhibitors | FOLH1, PSMA1, PSMA2 | HSD17B10 2817/4885SIGMAR1 3119/4885SLC6A9 256/4885 |
| US-20170072075-A1 | Chelated PSMA Inhibitors | FOLH1, KLK3, PSMA1 | HSD17B10 3737/4885SIGMAR1 3316/4885SLC6A9 2709/4885 |
| US-10919937-B2 | Bicyclic peptide ligands and uses thereof | VIP, NGLY1, BID | HSD17B10 4052/4885SIGMAR1 1240/4885SLC6A9 4691/4885 |
| US-20210079045-A1 | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE MOIETIES AND USES THEREOF | VIP, NGLY1, GRPR | HSD17B10 4114/4885SIGMAR1 1983/4885SLC6A9 4781/4885 |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | HSD17B10 3848/4885SIGMAR1 231/4885SLC6A9 2603/4885 |
| US-20200061218-A1 | Albumin-Binding PSMA Inhibitors | PSMA1, ALB, PSMA2 | HSD17B10 3053/4885SIGMAR1 3315/4885SLC6A9 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.